Authorship：Corresponding author   Publishing type：Research paper (scientific journal)   Publisher：Royal Society of Chemistry (RSC)  

Diabetes mellitus deteriorates the performance of small-caliber PCL graft and insulin treatment rescues the function.

DOI： 10.1039/d2bm00531j

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Background/objectives: Decrease in skeletal muscle mass and function is associated with a poor prognosis following surgical resection of pancreatic ductal adenocarcinomas (PDAs). This study evaluated whether skeletal muscle mass decrease affects PDA outcomes. Methods: Data of 112 patients with advanced and unresectable PDA who underwent chemotherapy in a single institution were retrospectively analyzed. Information on age, sex, hematological investigations, including systemic inflammation-based markers and nutritional assessment biomarkers, and imaging parameters of skeletal muscle mass and visceral adipose tissue were retrieved from the patients’ medical records. The efficiency of the Cox, Weibull, and standardized exponential models were compared using hazard ratios and the Akaike Information Criterion (AIC). Results: Results from the Weibull, Cox, and standardized exponential model analyses indicated that low skeletal muscle mass, Eastern Cooperative Oncology Group performance status (PS), and the requirement of biliary drainage were associated with the highest risk of death, followed by carcinoembryonic antigen (CEA) levels and the presence of ascites. The AIC value from the four significant parameters was lowest for the Weibull-exponential distribution (222.3) than that of the Cox (653.7) and standardized exponential models (265.7). We developed a model for estimating the 1-year survival probability using the Weibull-exponential distribution. Conclusions: Low-skeletal muscle index, PS, requirement of biliary drainage, CEA levels, and presence of ascites are independent factors for predicting poor patient survival after chemotherapy. Improved survival modeling using a parametric approach may accurately predict the outcome of patients with advanced-stage PDA.

DOI： 10.1016/j.pan.2021.03.002

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cardiovascular disease is the most common cause of death in the world. In severe cases, replacement or revascularization using vascular grafts are the treatment options. While several synthetic vascular grafts are clinically used with common approval for medium to large-caliber vessels, autologous vascular grafts are the only options clinically approved for small-caliber revascularizations. Autologous grafts have, however, some limitations in quantity and quality, and cause an invasiveness to patients when harvested. Therefore, the development of small-caliber synthetic vascular grafts (<5 mm) has been urged. Since small-caliber synthetic grafts made from the same materials as middle and large-caliber grafts have poor patency rates due to thrombus formation and intimal hyperplasia within the graft, newly innovative methodologies with vascular tissue engineering such as electrospinning, decellularization, lyophilization, and 3D printing, and novel polymers have been developed. This review article represents topics on the methodologies used in the development of scaffold-based vascular grafts and the polymers used <i>in vitro</i> and <i>in vivo</i>.

DOI： 10.3389/fcvm.2020.592361

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Japan  

The article “Hypothermic circulatory arrest induced coagulopathy: rotational thromboelastometry analysis”, written by Hayato Ise, Hiroto Kitahara, Kyohei Oyama, Keiya Takahashi, Hirotsugu Kanda, Satoshi Fujii, Takayuki Kunisawa, Hiroyuki Kamiya, was originally published electronically on the publisher’s internet portal on 7 June 2020 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 25 June 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https ://creat iveco mmons .org/licen ses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

DOI： 10.1007/s11748-020-01416-0

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The Polycomb repressive complex 2 (PRC2) is a multicomponent histone H3K27 methyltransferase complex, best known for silencing the Hox genes during embryonic development. The Polycomb-like proteins PHF1, MTF2, and PHF19 are critical components of PRC2 by stimulating its catalytic activity in embryonic stem cells. The Tudor domains of PHF1/19 have been previously shown to be readers of H3K36me3 in vitro. However, some other studies suggest that PHF1 and PHF19 co-localize with the H3K27me3 mark but not H3K36me3 in cells. Here, we provide further evidence that PHF1 co-localizes with H3t in testis and its Tudor domain preferentially binds to H3tK27me3 over canonical H3K27me3 in vitro. Our complex structures of the Tudor domains of PHF1 and PHF19 with H3tK27me3 shed light on the molecular basis for preferential recognition of H3tK27me3 by PHF1 and PHF19 over canonical H3K27me3, implicating that H3tK27me3 might be a physiological ligand of PHF1/19.

DOI： 10.7554/elife.58675

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s11748-020-01399-y

researchmap

Publishing type：Research paper (scientific journal)  

DOI： 10.1088/1748-605x/ab54e3

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s13072-018-0187-z

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.yjmcc.2018.05.013

researchmap

Publishing type：Research paper (scientific journal)  

DOI： 10.3389/fgene.2014.00375

researchmap

Publishing type：Research paper (scientific journal)  

DOI： 10.4236/jbpc.2014.52003

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/cr.2013.78

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1371/journal.pone.0058319

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：The Pharmaceutical Society of Japan  

This study demonstrated gemcitabine-induced cytotoxicity in the insulinoma cell line INS-1. Gemcitabine inhibited INS-1 cell proliferation and maintained consistent cell number for 24 h, and then caused apoptosis within 48 h of incubation. Since gemcitabine activates the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway, which is involved in the resistance of pancreatic exocrine cancer to gemcitabine, we investigated the participation of this pathway in gemcitabine-induced cytotoxicity in INS-1 cells. LY294002 and wortmannin, two PI3-K inhibitors, significantly prevented gemcitabine-induced cytotoxicity in INS-1 cells, indicating that the PI3-K/Akt pathway is involved in gemcitabine-induced cytotoxicity. Gemcitabine-induced Akt phosphorylation in INS-1 cells was prevented by LY294002. Although gemcitabine induced cell cycle arrest at the G1 and early S phases, LY294002 did not inhibit the cell cycle. These data suggest that PI3-K activation does not influence gemcitabine-induced cell cycle arrest. In gemcitabine-treated cells, nuclear fragmentation and DNA ladder formation were observed. These findings suggest that gemcitabine induced apoptotic cell death in INS-1 cells through the activation of the PI3-K/Akt pathway.

DOI： 10.1248/bpb.b12-00298

PubMed

CiNii Books

researchmap

Other Link： https://jlc.jst.go.jp/DN/JALC/10010682585?from=CiNii

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：The Pharmaceutical Society of Japan  

Cell cycle arrest is associated with differentiation, senescence and apoptosis. We investigated alterations in the cell cycle during the development of hypertrophy induced by hydrogen peroxide (H(2)O(2)) in the H9c2 clonal myoblastic cell line. H(2)O(2) induced hypertrophy in H9c2 cells that was indicated by an increase in atrial natriuretic peptide (ANP) gene expression, a marker of cardiomyocyte hypertrophy, and a larger cell size. On induction of hypertrophy by H(2)O(2) in H9c2 cells, cell proliferation was arrested, indicated by the number of cells remaining constant during a 72-h incubation period. The cell cycle was arrested at the G1 and G2/M phases with an increase in p21 expression, a negative cell cycle regulator. Cell cycle arrest and increase in p21 expression were significantly inhibited by 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra (acetoxymethyl) ester (BAPTA-AM), an intracellular calcium chelator. Although ANP gene expression was induced significantly, H(2)O(2) failed to induce hypertrophy in the presence of BAPTA-AM, and the cell cycle progressed. We concluded that H(2)O(2) induced cell cycle arrest in H9c2 cells, which was related to cellular hypertrophy.

DOI： 10.1248/bpb.34.501

PubMed

CiNii Books

researchmap

Other Link： https://jlc.jst.go.jp/DN/JALC/00365805050?from=CiNii

Publishing type：Research paper (scientific journal)  

DOI： 10.4236/jbpc.2011.21002

researchmap

Publishing type：Research paper (scientific journal)  

DOI： 10.4236/jbpc.2010.13019

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3164/jcbn.09-47

researchmap

Event date： 2023.6

Language：English   Presentation type：Symposium, workshop panel (nominated)  

researchmap

Event date： 2023.6

Language：English   Presentation type：Poster presentation  

researchmap

Event date： 2023.3

Language：English   Presentation type：Oral presentation (general)  

researchmap

Event date： 2023.3

Language：English   Presentation type：Oral presentation (general)  

Venue：旭川市民文化会館・星野リゾートOMO7 旭川・アートホテル旭川  

researchmap

Event date： 2022.11 - 2022.12

Language：Japanese   Presentation type：Poster presentation  

researchmap

Event date： 2022.11 - 2022.12

Language：English   Presentation type：Oral presentation (general)  

Venue：幕張メッセ  

researchmap

Event date： 2022.11 - 2022.12

Language：English   Presentation type：Poster presentation  

Venue：幕張メッセ  

researchmap

Event date： 2022.11

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Venue：愛媛県県民文化会館  

researchmap

Event date： 2022.2

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2021.10 - 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2021.10 - 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2021.2

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2020.11

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2020.8 - 2020.9

Language：Japanese   Presentation type：Poster presentation  

researchmap

Event date： 2020.5

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2020.2

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2019.12

Language：Japanese   Presentation type：Oral presentation (invited, special)  

researchmap

Event date： 2019.10 - 2019.11

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Event date： 2018.5

Language：Japanese   Presentation type：Poster presentation  

researchmap